Answers are grounded in this paper and cite their sources.
Doxorubicin as an anticancer drug has myelosuppressive side effects. This study aimed to investigate the possibility of myeloprotective role of the natural antioxidant Curcuma xanthorrhiza, Zingiber officinale, and Curcuma domestica in rats induced by doxorubicin. Wistar male rats were divided into four groups and treated with (1) 0.9% NaCl as a control group, (2) doxorubicin 5 mg/kg intraperitoneally, 4 times in 14 days (days 1, 5, 9, 13); (3) doxorubicin + extract 250 mg/kg/day orally for 14 days; (4) doxorubicin + extract of 500 mg/kg/day orally for 14 days. Blood samples of rats were taken on day 15th and sacrificed for harvesting spleen organ. White blood cells were counted, and spleen weights were evaluated as markers of myelosuppressive effect. The amount of white blood cells and spleen weights were reduced in the doxorubicin treated groups. Whereas in the group treated by the extract (250 mg and 500 mg) + doxorubicin, the amount of white blood cells and spleen weights were increased. These results indicated that the extract combination of Curcuma xanthorrhiza, Zingiber officinale, and Curcuma domestica has myeloprotective activity by keeping the amount of white blood cells and spleen weights.
No takes yet. Share an insight, caveat, or question.
Ekowati et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: